Name /Chia Soo
Telephone /(Work) 0987-251423
Saint Therapeutics is a biotechnology startup focused on revolutionizing tissue repair and disrupting the billion-dollar scar prevention, scar reduction, and chronic wound healing industries. Building upon over 20 years of research into how fetal skin rapidly heals without scarring, Saint Therapeutics has developed a novel peptide drug, SLI-F06, that significantly reduces scar formation after surgeries and accelerates wound healing.
Inspired by fibromodulin found in fetal tissue, Saint Therapeutics has created a novel peptide drug, SLI-F06, that recreates rapid, scar-free fetal-type repair. SLI-F06 activates fibroblasts, the main cell-type responsible for skin and soft tissue healing, making fibroblasts work better (less scarring, stronger wound tensile strength) and faster (more healing) to both decrease scar formation and promote chronic wound healing. SLIF06 is an injectable peptide for use during surgery. It is intended as an acute treatment to allow patients to heal faster, better, and with much less scarring. SLIF06 has completed Phase 1 without drug-related adverse events and Phase 2a with preliminary evidence of significantly improved scar appearance on the treated side at the long-term. Additionally, SLI-F06 is a platform technology that will allow Saint Therapeutics to offer multiple product verticals after tackling the closed wound scar reduction market. These applications include chronic wound healing (e.g. diabetic ulcers), tendon / fascia / muscle healing, and anti-fibrotic coatings.
Name /YUNG YI CHEN